Adrenal Gland Cancer is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Adrenal Gland Cancer have a 50% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Adrenal Gland Cancer compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Adrenal Gland Cancer overview
Adrenal gland cancer is a rare type of neuroendocrine tumor that originates from the cells of the adrenal glands, which are located on top of the kidneys. The adrenal glands produce hormones that regulate various functions in the body, such as blood pressure, metabolism, stress response, and sex drive. Adrenal gland cancer can affect the production of these hormones, causing symptoms such as weight gain, muscle weakness, high blood pressure, hair growth, and mood changes. Adrenal gland cancer can be benign or malignant. The most common malignant adrenal gland cancer is adrenocortical carcinoma, which starts in the outer layer of the adrenal glands. Adrenal gland cancer can be diagnosed with blood tests, urine tests, imaging tests, and biopsy. Treatment options include surgery, radiation therapy, chemotherapy, and targeted therapy.
For a complete picture of PTSR and LoA scores for drugs in Adrenal Gland Cancer, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
